Alvotech (ALVO) - News Archive

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines, has recently released its financial results for the full year 2023. The company also provided an update on its...

Alvotech, a leading biotech company focused on developing and manufacturing biosimilar medicines, is preparing to announce its full-year 2023 financial results. With its commitment to providing patients worldwide with a...

Alvotech Announces Sale of Ordinary Shares to Investors Worth $166 Million, Impact on Shareholders ExploredREYKJAVIK, Iceland, Feb. 26, 2024 - Alvotech, a leading biotech company focusing on biosimilar medicines, reveal...

REYKJAVIK, Iceland & PARSIPPANY, N.J. - Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have achieved a groundbreaking milestone with thei...

Alvotech Set to Make Global Impact with Biosimilar Entry for AVT04Icelandic biotech company, Alvotech, has recently announced its expected market entry dates for AVT04, a biosimilar to Stelara (ustekinumab), in several...

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and XgevaAlvotech (NASDAQ: ALVO), a global biotech company dedicated to developing and manufacturing...

Biotech company Alvotech has recently announced the completion of the reinspection of its facility in Iceland by the U.S. Food and Drug Administration (FDA). The inspection, which commenced on January 10, 2024, resulted...

Leading international pharmaceutical powerhouses, STADA and Alvotech, celebrated another significant milestone, bagging the European Commission s marketing authorization approval for Uzpruvo(AVT04), a biosimilar candida...

Alvotech, a renowned biotech company focusing on the development and production of biosimilar medications for patients worldwide, has recently unveiled encouraging top-line results from a confirmatory clinical study for...